by FiveSenses | Nov 21, 2025 | News Release
Montreal, QC, Canada, November 21st, 2025 – Defence Therapeutics Inc. (“Defence” or the “Company”), a leading biotechnology company pioneering next-generation antibody-drug conjugate (“ADC”), announces that the holders of the Corporation’s 8% convertible... 
by FiveSenses | Nov 19, 2025 | News Release
Montreal, QC, Canada, November 19th, 2025 – Defence Therapeutics Inc. (“Defence” or the “Company”), a leading biotechnology company pioneering next-generation antibody-drug conjugate (“ADC”), is pleased to announce a major step forward in the fight against... 
by FiveSenses | Nov 7, 2025 | News Release
Montreal, QC, Canada, November 6th, 2025 – Defence Therapeutics Inc. (“Defence” or the “Company”), a leading biotechnology company pioneering next-generation antibody-drug conjugate (“ADC”), is pleased to announce the successful presentation of new data on its... 
by FiveSenses | Nov 4, 2025 | News Release
Montreal, QC, Canada, November 4th, 2025 – Defence Therapeutics Inc. (“Defence” or the “Company”), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce and to present today at the World ADC Conference in San Diego,...
Recent Comments